Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study

The aim of this multicentre study was to assess the usefulness of prostate-specific antigen (PSA) as a diagnostic procedure for prostate cancer in patients with urological symptoms, and compare it with digital rectal examination (DRE). The study included 2054 urological patients, aged over 50 years,...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 1996-06, Vol.32 (7), p.1125-1128
Main Authors: Filella, X, Molina, R, Ballesta, A.M, Gil, M.J, Allepuz, C, Rioja, L.A
Format: Article
Language:English
Subjects:
Age Distribution
Aged
Aged, 80 and over
Biological and medical sciences
Biomarkers, Tumor - blood
Humans
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Palpation
Prospective Studies
prostate cancer
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - complications
Prostatic Neoplasms - diagnosis
PSA
Rectum
Tumors of the urinary system
Urinary tract. Prostate gland
Urologic Diseases - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this multicentre study was to assess the usefulness of prostate-specific antigen (PSA) as a diagnostic procedure for prostate cancer in patients with urological symptoms, and compare it with digital rectal examination (DRE). The study included 2054 urological patients, aged over 50 years, and PSA levels were measured using an automated enzyme immunoassay. In the 680 cases with PSA levels >3 μg/l and/or suspect DRE, transrectal ultrasound and prostate biopsy were also performed, leading to a diagnosis of cancer in 131 cases. The sensitivity of PSA was higher (95% and 73% for the cut-off values of 3 and 10 μg/l, respectively) than DRE (69%), both parameters being complementary. When DRE and PSA (>10 μg/l) were combined, 118 cancers were diagnosed, with a PPV of 37%. We recommend using PSA and DRE in combination as a diagnostic procedure for prostate cancer in urological patients, since both methods are complementary.
ISSN:0959-8049
1879-0852
DOI:10.1016/0959-8049(96)00092-5